Ngā hua rapu - Andrew Howman
- E whakaatu ana i te 1 - 4 hua o te 4
-
1
-
2
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials mā Keith Wheatley, Cassandra Brookes, Andrew Howman, Anthony H. Goldstone, Donald Milligan, A. G. Prentice, Anthony V. Moorman, Alan K. Burnett
I whakaputaina 2009Artigo -
3
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial mā Andrew Howman, Tracey L Chapman, Maria M Langdon, Caroline Ferguson, Dwomoa Adu, John Feehally, G. Gaskin, David Jayne, Dónal O’Donoghue, Michael Boulton-Jones, Peter W. Mathieson
I whakaputaina 2013Artigo -
4
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04) mā Simon Bailey, Andrew Howman, Keith Wheatley, Dee Wherton, N. Boota, Barry Pizer, Darrel R. Fisher, Pamela Kearns, Susan Picton, Frank Saran, M. Gibson, Adam Glaser, Daniel Connolly, Darren Hargrave
I whakaputaina 2013Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Internal medicine
Medicine
Chemotherapy
Clinical trial
Oncology
Randomized controlled trial
Cyclophosphamide
Surgery
Anthracycline
Breast cancer
Cancer
Cancer research
Chlorambucil
Ciclosporin
Clinical endpoint
Confidence interval
Creatinine
Cytarabine
Dacarbazine
Daunorubicin
Diabetes mellitus
Endocrinology
Etoposide
Glioma
Glomerulonephritis
Hazard ratio
Idarubicin
Immunosuppression
Induction chemotherapy
Interim analysis